Search the Newsreel

Gallantt Ispat maintains 18% EBITDA margin in Q1FY27 despite cost pressures

Southern Hemisphere Mining (ASX: SUH) Share Update: Llahuin Drilling Intersects Extensive Copper Mineralisation in Chile

China Display Optoelectronics Shifts Bermuda Registered Office, Keeps Hong Kong Registrar Unchanged

Crispr Therapeut (CRSP) Stock News & Updates

This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor …

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago. These figures are adjusted for non-recurring items. This …

Crispr Therapeutics earnings beat by $0.26, revenue topped estimates

Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses …

Crispr Therapeutics AG (CRSP) rebounds 3.1% before Aug. 3 earnings, but trend stays inactive

The gene-editing biotech reports with medium-term performance still under pressure and volume running below its 13-week average.

CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose …

Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M

CRISPR Therapeutics AG (CRSP) reported Q2 revenue of $10.2 million, significantly surpassing the FactSet estimate of $7.4 million. This earnings flash highlights the company's financial performance for the second quarter and six months ended June 30, 2026. The article also mentions the company's recent …

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph.D., Chairman and …

CRISPR Therapeutics reports $91.2 million second quarter net loss

CRISPR Therapeutics (CRSP) reported a net loss of $91.2 million for the second quarter of 2026, a significant improvement from the $208.5 million loss in the same period last year, while total revenue increased to $10.2 million. The company's gene-editing therapy, CASGEVY, generated $76 …

Krispy Kreme Promotes Suk Nicholas and Lori Suess to Executive Leadership Roles

Krispy Kreme Inc. (NASDAQ: DNUT) has promoted Suk Nicholas to Chief Commercial Officer and Lori Suess to Chief People Officer, effective August 3, 2026. These appointments aim to strengthen the company's leadership and support its long-term growth strategy. Nicholas will oversee the fresh delivery …

Krispy Kreme promotes two officials to executive leadership roles

Krispy Kreme has announced the promotion of Suk Nicholas to Chief Commercial Officer and Lori Suess to Chief People Officer. Both officials assumed their new roles on Monday and are now members of the company's global leadership team. Joshua Charlesworth, Krispy Kreme President and …

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share

CRISPR Therapeutics AG (CRSP) reported a Q2 loss of $0.94 per share on revenue of $10.18 million, missing analyst revenue estimates but exceeding them on earnings per share. The company saw significant growth in revenue from its lead drug, CASGEVY, with a 151% year-over-year …

Krispy Kreme names new commercial, people chiefs

Krispy Kreme Inc. has appointed Suk Nicholas as Chief Commercial Officer and Lori Suess as Chief People Officer. Nicholas will lead the company’s fresh delivery business and sales strategies, while Suess will oversee global people, culture, and talent development. These promotions aim to strengthen …

Unlocking Universal Display (OLED) International Revenues: Trends, Surprises, and Prospects

Did you analyze how Universal Display Corp. (OLED) fared in its international operations for the quarter ending June 2026? Given the widespread global presence of this organic light-emitting diode technology company, scrutinizing the trends in international revenues becomes imperative to assess its financial strength …

Krispy Kreme, Inc. Announces Management Changes, Effective August 3, 2026

Krispy Kreme, Inc. announced significant management changes effective August 3, 2026. Suk Nicholas has been appointed as Chief Commercial Officer, where she will lead the Company's fresh delivery business in the U.S. and internationally. Lori Suess has been named Chief People Officer, overseeing global …

Krispy Kreme Names Suk Nicholas Chief Commercial Officer and Lori Suess Chief People Officer

Krispy Kreme has announced two key leadership appointments: Suk Nicholas as Chief Commercial Officer and Lori Suess as Chief People Officer, effective August 3, 2026. Ms. Nicholas will lead the company's fresh delivery business and sales strategies, leveraging her 15 years of experience within …

Universal Display expects 2026 revenue around the low end of $630M-$670M

Universal Display Corporation reported its second-quarter 2026 financial results, with total revenue reaching $152.2 million, a decrease from $171.8 million in Q2 2025. The company revised its 2026 revenue guidance to the lower end of its previously projected range of $630 million to $670 …

Gallantt Ispat Consolidated June 2026 Net Sales at Rs 1,145.67 crore, up 1.59% Y-o-Y

CRISPR Therapeutics (CRSP) Expected to Release Earnings on Monday

CRISPR Therapeutics (CRSP) is anticipated to release its Q2 2026 earnings on Monday, August 10th, with analysts forecasting a loss of $1.20 per share and revenue of $7.45 million. The company's shares are currently trading near their 52-week low, and it remains unprofitable, though …

Universal Display (OLED) Stock Still Looks Reasonable After Lowered Revenue Outlook

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Universal Display stock has fallen a long way over the past few years, yet the current market multiples still suggest the shares may …

Universal Display Corporation $OLED Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Universal Display Corporation ($OLED) during the first quarter, purchasing an additional 222,561 shares, bringing its total holdings to 251,218 shares valued at approximately $23 million. Other institutional investors also adjusted their positions in the semiconductor …

Universal Display (OLED) Could Be 37% Undervalued After Lowered 2026 Guidance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Universal Display (OLED) just released second quarter 2026 results that showed lower revenue and …

Is Universal Display (OLED) Below Fair Value After Lower Guidance?

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P …

Universal Display Corporation $OLED Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its stake in Universal Display Corporation (OLED) by 9.8% in the first quarter, selling 29,126 shares but retaining 268,760 shares valued at approximately $24.6 million. Despite beating EPS estimates in Q2, the company's revenue declined 11.4% year-over-year and …

CRSP Stock Price and Chart — NASDAQ:CRSP

This page provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial statistics, and company details. It also features a collection of recent news and trading ideas from analysts and community members regarding CRSP's stock movement, …

Universal Display (OLED) Stock Faces Margin Squeeze As Revenue Slips

LG Display Co, Ltd AMERICAN DEPOSITORY SHARES Stock 12‑Month Price Target Cut to $4.13, Implies 38% Upside

LG Display Co, Ltd's (034220) average 12-month stock price target has been lowered from $4.24 to $4.13 by 10 analysts, with a range of $2.87 to $5.4 per share. This new target suggests a potential 38% upside from the July 31 closing price. Despite …

OLED Q2 Deep Dive: Weak Smartphone Demand and Supply Chain Headwinds Shape Outlook

OLED Q2 Deep Dive: Weak Smartphone Demand and Supply Chain Headwinds Shape Outlook OLED provider Universal Display (NASDAQ:OLED) fell short of the market's revenue expectations in Q2 CY2026, with sales falling 11.4% year on year to $152.2 million. On the other hand, the company's …

INTESA SANPAOLO S.P.A.: Intesa Sanpaolo meldet Rekordergebnis für das erste Halbjahr und hebt Prognosen an

Needham cuts Universal Display stock price target on weak smartphone demand

Needham has lowered its price target for Universal Display (NASDAQ:OLED) to $100 from $120, while maintaining a Buy rating, due to weak smartphone demand and higher memory costs that led the company to revise its revenue guidance. Despite near-term challenges and recent mixed Q2 …

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK)

This article discusses mixed analyst opinions on two healthcare stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK). Crispr Therapeutics received a "Moderate Buy" consensus with an attractive price target upside, while GlaxoSmithKline holds a "Hold" consensus with a modest upside. The report highlights specific …

CRISPR Therapeutics AG (CRSP) Financial Health: Profitability & Balance Sheet Analysis

CRISPR Therapeutics AG (CRSP) has a weak financial status with a current financial score of 6.45, ranking 242 out of 384 in its industry. Despite a 68.55% year-over-year revenue increase to $1.46M and a 9.61% net profit increase, its operating efficiency is low. The …

Southern Hemisphere Mining (ASX:SUH): Deeper Chilean Copper Drilling Draws Fresh Attention